Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

Menglu Zhao; Chun-Yan Yan; Ya-Nan Wei; Xi-He Zhao

doi:10.1016/j.antiviral.2023.105720

Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

Antiviral Res. 2023 Nov:219:105720. doi: 10.1016/j.antiviral.2023.105720. Epub 2023 Sep 23.

Authors

Menglu Zhao¹, Chun-Yan Yan¹, Ya-Nan Wei¹, Xi-He Zhao²

Affiliations

¹ Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, PR China.
² Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, PR China. Electronic address: zhaoxh@sj-hospital.org.

PMID: 37748652
DOI: 10.1016/j.antiviral.2023.105720

Abstract

Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapy-resistant cancer.

Keywords: Antibody drug conjugate (ADC); Bispecific antibody; Drug resistance; PD-L1.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Neoplasms* / drug therapy
Programmed Cell Death 1 Receptor

Substances

Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor